癌症治疗中辐射诱导药物控制释放的敏化剂和脂质体组合物的比较研究。
A comparative study of sensitizers and liposome composition in radiation-induced controlled drug release for cancer therapy.
发表日期:2024 Sep 11
作者:
E Loscertales, J Mateo, S España
来源:
JOURNAL OF LIPOSOME RESEARCH
摘要:
这项研究研究了设计用于电离辐射下控释的载药脂质体,以提高癌症治疗的精度。脂质体作为载体可以实现靶向化疗,降低健康组织损伤的风险。评估了含有多不饱和脂肪酸或单不饱和脂肪酸和各种敏化剂的脂质体对紫外线和 γ 光子照射的反应性,包括玫瑰红 (RB)、原卟啉 IX (PPIX)、维替泊芬 (VP)、尾孢菌素 (CERC) 和金丝桃素。 HYP)。羧基荧光素 (CF) 用作药物释放测量的替代物。 VP和PPIX在紫外光下诱导药物快速释放和脂质过氧化,而RB在紫外光下促进药物快速释放,并在γ照射下适度立即释放,最终在照射后几小时达到完全释放,表现出剂量依赖性效应。较小的脂质体表现出加速释放,强调尺寸依赖性动力学。体外分析评估了负载 RB 的脂质体的放射增敏作用。克隆形成试验表明,RB 填充的脂质体具有最小的直接放射生物学效应,但增加了间接辐射损伤,如细胞存活曲线的曲率所示。我们的研究揭示了电离辐射下影响脂质体药物释放的因素,强调 RB 作为一种有前途的放射增敏剂,需要进一步研究其癌症治疗潜力。
This study investigates drug-loaded liposomes designed for controlled release under ionizing radiation to refine cancer treatment precision. Liposomes as carriers enable targeted chemotherapy delivery, reducing healthy tissue damage risk. Liposomes containing poly- or mono-unsaturated fatty acids and various sensitizing agents were assessed for responsiveness to UV light and γ photon irradiation including rose bengal (RB), protoporphyrin IX (PPIX), verteporfin (VP), cercosporin (CERC) and hypericin (HYP). Carboxyfluorescein (CF) was used as a surrogate for drug release measurements. VP and PPIX induced rapid drug release and lipid peroxidation under UV light, while RB prompted quick drug release under UV light and a modest immediate release under γ irradiation, eventually reaching full release a few hours after irradiation, demonstrating dose-dependent effects. Smaller liposomes displayed accelerated release, emphasizing size-dependent kinetics. In vitro analyses evaluated radiosensitizing effects of RB-loaded liposomes. Clonogenic assays indicated that RB-filled liposomes had minimal direct radiobiological effects but increased indirect radiation damage, as shown by the curvature of the cell survival curve. Our study sheds light on factors influencing liposomal drug release under ionizing radiation, spotlighting RB as a promising radiosensitizer requiring further investigation for cancer therapy potential.